These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 30739635)

  • 1. Actigraphy as an assessment of performance status in patients with advanced lung cancer.
    Fujisawa D; Temel JS; Greer JA; El-Jawahri A; Traeger L; Jacobs JM; Cutrono S; Pirl WF
    Palliat Support Care; 2019 Oct; 17(5):574-578. PubMed ID: 30739635
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparing Physician and Nurse Eastern Cooperative Oncology Group Performance Status (ECOG-PS) Ratings as Predictors of Clinical Outcomes in Patients with Cancer.
    Neeman E; Gresham G; Ovasapians N; Hendifar A; Tuli R; Figlin R; Shinde A
    Oncologist; 2019 Dec; 24(12):e1460-e1466. PubMed ID: 31227648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Physical Activity Using a Wearable Device as an Alternative to Performance Status in Patients With Advanced Lung Cancer.
    Ito K; Suzuki Y; Sakaguchi T; Fujiwara K; Nishii Y; Yasui H; Taguchi O; Hataji O
    JAMA Oncol; 2024 May; 10(5):648-651. PubMed ID: 38546663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Should patient-rated performance status affect treatment decisions in advanced lung cancer?
    Dajczman E; Kasymjanova G; Kreisman H; Swinton N; Pepe C; Small D
    J Thorac Oncol; 2008 Oct; 3(10):1133-6. PubMed ID: 18827609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Surgical results of metastatic spinal cord compression (MSCC) from non-small cell lung cancer (NSCLC): analysis of functional outcome, survival time, and complication.
    Park SJ; Lee CS; Chung SS
    Spine J; 2016 Mar; 16(3):322-8. PubMed ID: 26586194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quality of life assessment in advanced non-small-cell lung cancer patients undergoing an accelerated radiotherapy regimen: report of ECOG study 4593. Eastern Cooperative Oncology Group.
    Auchter RM; Scholtens D; Adak S; Wagner H; Cella DF; Mehta MP
    Int J Radiat Oncol Biol Phys; 2001 Aug; 50(5):1199-206. PubMed ID: 11483329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Performance status agreement assessed by the patient and clinician in a rapid access lung cancer service: Can either predict completion of treatment?
    Collins JT; Noble S; Davies HE; Farewell D; Lester JF; Parry D; Byrne A
    Eur J Cancer Care (Engl); 2019 May; 28(3):e13004. PubMed ID: 30761639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of nutrition parameters including bioelectrical impedance and systemic inflammatory response with quality of life and prognosis in patients with advanced non-small-cell lung cancer: a prospective study.
    Sánchez-Lara K; Turcott JG; Juárez E; Guevara P; Núñez-Valencia C; Oñate-Ocaña LF; Flores D; Arrieta O
    Nutr Cancer; 2012; 64(4):526-34. PubMed ID: 22489794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FACT-Hep increases the accuracy of survival prediction in HCC patients when added to ECOG Performance Status.
    Gmür A; Kolly P; Knöpfli M; Dufour JF
    Liver Int; 2018 Aug; 38(8):1468-1474. PubMed ID: 29389088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Objective assessment of WHO/ECOG performance status.
    Sok M; Zavrl M; Greif B; Srpčič M
    Support Care Cancer; 2019 Oct; 27(10):3793-3798. PubMed ID: 30721369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between subjective and actigraphy-measured sleep in 237 patients with metastatic colorectal cancer.
    Palesh O; Haitz K; Lévi F; Bjarnason GA; Deguzman C; Alizeh I; Ulusakarya A; Packer MM; Innominato PF
    Qual Life Res; 2017 Oct; 26(10):2783-2791. PubMed ID: 28656534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discrepancies between genitourinary cancer patients' and clinicians' characterization of the Eastern Cooperative Oncology Group performance status.
    Bergerot CD; Philip EJ; Bergerot PG; Hsu J; Dizman N; Salgia M; Salgia N; Vaishampayan U; Battle D; Loscalzo M; Dale W; Pal SK
    Cancer; 2021 Feb; 127(3):354-358. PubMed ID: 33007114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The clinical role of VeriStrat testing in patients with advanced non-small cell lung cancer considered unfit for first-line platinum-based chemotherapy.
    Lee SM; Upadhyay S; Lewanski C; Falk S; Skailes G; Woll PJ; Hatton M; Lal R; Jones R; Toy E; Rudd R; Ngai Y; Edwards A; Hackshaw A
    Eur J Cancer; 2019 Oct; 120():86-96. PubMed ID: 31499384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a patient-centered aggregate score to predict survival after lung resection for non-small cell lung cancer.
    Brunelli A; Salati M; Refai M; Xiumé F; Berardi R; Mazzanti P; Pompili C
    J Thorac Cardiovasc Surg; 2013 Aug; 146(2):385-90.e1-2. PubMed ID: 23651911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Baseline quality of life and performance status as prognostic factors in patients with extensive-stage disease small cell lung cancer treated with pemetrexed plus carboplatin vs. etoposide plus carboplatin.
    Reck M; Thatcher N; Smit EF; Lorigan P; Szutowicz-Zielinska E; Liepa AM; Winfree KB; Peterson P; Guba SC; Socinski MA
    Lung Cancer; 2012 Dec; 78(3):276-81. PubMed ID: 23043970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival Prediction in Ambulatory Patients With Stage III/IV Non-Small Cell Lung Cancer Using the Palliative Performance Scale, ECOG, and Lung Cancer Symptom Scale.
    O'Mahony S; Nathan S; Mohajer R; Bonomi P; Batus M; Fidler MJ; Wells K; Kern N; Sims S; Amin D
    Am J Hosp Palliat Care; 2016 May; 33(4):374-80. PubMed ID: 25670717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The humanistic burden of advanced non-small cell lung cancer (NSCLC) in Europe: a real-world survey linking patient clinical factors to patient and caregiver burden.
    Wood R; Taylor-Stokes G; Smith F; Chaib C
    Qual Life Res; 2019 Jul; 28(7):1849-1861. PubMed ID: 30825160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pembrolizumab for advanced nonsmall cell lung cancer: Efficacy and safety in everyday clinical practice.
    Ksienski D; Wai ES; Croteau N; Freeman AT; Chan A; Fiorino L; Brooks EG; Poonja Z; Fenton D; Geller G; Irons S; Lesperance M
    Lung Cancer; 2019 Jul; 133():110-116. PubMed ID: 31200816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation between the international consensus definition of the Cancer Anorexia-Cachexia Syndrome (CACS) and patient-centered outcomes in advanced non-small cell lung cancer.
    LeBlanc TW; Nipp RD; Rushing CN; Samsa GP; Locke SC; Kamal AH; Cella DF; Abernethy AP
    J Pain Symptom Manage; 2015 Apr; 49(4):680-9. PubMed ID: 25461669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single-agent gefitinib in patients with untreated advanced non-small-cell lung cancer and poor performance status: a Minnie Pearl Cancer Research Network Phase II Trial.
    Spigel DR; Hainsworth JD; Burkett ER; Burris HA; Yardley DA; Thomas M; Jones SF; Dickson NR; Scullin DC; Bradof JE; Rubinsak JR; Brierre JE; Greco FA
    Clin Lung Cancer; 2005 Sep; 7(2):127-32. PubMed ID: 16179100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.